Skip to main content

Cingulate, Inc. (CING)

Cingulate will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Market Capn/a
Revenue (ttm)n/a
Net Income (ttm)-5.10M
Shares Outn/a
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About CING

Cingulate is a clinical stage biopharmaceutical company using our proprietary Precision Timed Release, or PTR, drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. We are initially focusing our efforts on the treatment of Attention Deficit/Hyperactivity Disorder, or ADHD. Our PTR platform incorporates a proprietary Ero...

IndustryPharmaceutical Preparations
IPO DatePending
CEOShane J. Schaffer
Employees13
Stock ExchangeNASDAQ
Ticker SymbolCING
Full Company Profile

Financial Performance

Financial Statements

News

Cingulate IPO Registration Document (S-1)

Cingulate, Inc. has filed to go public with an IPO on the NASDAQ.

1 week ago - SEC